Lexicon Pharmaceuticals Inc
Suletud
SektorTervishoid
2.02 1
Ülevaade
Aktsiahinna muutus
24h
Min
2
Max
2.04
Sissetulek | -32M -33M |
|---|---|
Müük | -20M 692K |
Aktsiakasum | -0.06 |
Kasumimarginaal | -4,742.486 |
Töötajad | 81 |
EBITDA | -30M -29M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +150.41% upside |
Järgmine tulemuste avaldamine | 5. nov 2026 |
|---|
Turukapital | -154M 881M |
|---|---|
Eelmine avamishind | 1.02 |
Eelmine sulgemishind | 2.02 |
Lexicon Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Lexicon Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
150.41% tõus
12 kuu keskmine prognoos
Keskmine 5.033 USD 150.41%
Kõrge 6 USD
Madal 3.1 USD
Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.